---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-026089"
form_type: "8-K"
ticker: "RANI"
cik: "0001856725"
company_name: "Rani Therapeutics Holdings, Inc."
filed_at: "2022-12-06T23:59:59+00:00"
generated_at: "2026-06-21T09:10:56.088751+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# RT-102 repeat-dose Phase 1 meets endpoints; 91% delivery success, high bioavailability, supports Phase 2

## Summary
- No serious adverse events; all 10 participants completed 7-day daily dosing.
- RaniPill GO delivered PTH with 91% overall success; Day 7 success rate 100%.
- RT-102 showed high PTH bioavailability vs subcutaneous injection in Part 1.
- Company expects to initiate Phase 2 trial of RT-102 in osteoporosis in H2 2023.
- Over 185 RaniPill capsules administered in clinical studies; platform advancing for multiple programs.

## SEC filing metadata
- accession: 0000950170-22-026089
- form_type: 8-K
- ticker: RANI
- cik: 0001856725
- company_name: Rani Therapeutics Holdings, Inc.
- filed_at: 2022-12-06T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 9.01, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1856725/000095017022026089/0000950170-22-026089-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1856725/000095017022026089/rani-20221206.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-026089
- JSON: https://secwatch.observer/filing/0000950170-22-026089.json
- Plain text: https://secwatch.observer/filing/0000950170-22-026089.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.